Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 11/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 3/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499555 | 0.94 | RNASEL (0.56) | RNASELNT5EKRASTGM2ADORA1 | |
| SCHEMBL18510943 | 0.94 | RNASEL (0.59) | RNASELNT5EKRASTGM2P2RY2 | |
| SCHEMBL22399396 | 0.90 | NT5E (0.52) | NT5EKRASTGM2HPGDP2RY2 | |
| SCHEMBL21943191 | 0.88 | RNASEL (0.63) | RNASELADORA1 | |
| SCHEMBL22399223 | 0.87 | RNASEL (0.54) | RNASELNT5EKRASTGM2 | |
| SCHEMBL18521093 | 0.87 | RNASEL (0.64) | RNASELNT5ETGM2 | |
| SCHEMBL18521212 | 0.87 | RNASEL (0.64) | RNASELNT5ETGM2 | |
| SCHEMBL18510897 | 0.87 | RNASEL (0.64) | RNASELNT5ETGM2 | |
| SCHEMBL18520839 | 0.87 | RNASEL (0.64) | RNASELNT5ETGM2 | |
| SCHEMBL24499094 | 0.86 | RNASEL (0.54) | RNASELNT5EKRASTGM2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | RNASEL 1846/4885NT5E 56/4885KRAS 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.